Примери за използване на Treatment in patients на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
up to 22 weeks after completion of treatment in patients with chronic neck pain”.
Physicians should consider the delayed onset of nivolumab effect before initiating treatment in patients with rapidly progressing disease(see section 5.1).
analogue should be continued during treatment in patients not surgically castrated.
Surgical treatment in patients with an asymptomatic course of the disease is permissible only with poor performance tests.
Consideration should be given to discontinuing treatment in patients who have shown no response after 12-16 weeks of treatment. .
Consideration should be given to discontinuing treatment in patients who have shown no response after 3 months of treatment. .
To discontinue treatment in patients with Parkinson's disease,
Consideration should be given to discontinuing treatment in patients who have shown no response after 16 weeks of treatment for atopic dermatitis.
It is recommended that you stop treatment in patients with ALT or AST levels more than 3 times the ULN regardless of bilirubin levels.
The decision to continue treatment in patients who develop seizure should be taken case by case.
Further, the PRAC took into consideration that interrupting treatment in patients whose disease is well-controlled with daclizumab may induce relapses.
Upon initiation of treatment in patients with bone metastases with mild to moderate renal impairment,
Therefore fluoroquinolones should be reserved as a last line treatment in patients where other therapeutic options are not effective or not tolerated.
A Cochrane review concluded that antibiotic treatment in patients with acute bronchitis had a modest beneficial effect not outweighing the side-effects of treatment. .
Consideration should be given to discontinuing treatment in patients who have shown no response after 16 weeks of treatment. .
Consideration should be given to discontinuing treatment in patients who have shown no response after 16 weeks of treatment. .
Consideration should be given to discontinuing treatment in patients who have shown no response by 16 weeks of treatment. .
safe therapy for treatment in patients with mild depression.”.
Caution should be exercised when considering TNF-antagonist therapy for patients with a history of malignancy or when considering continuing treatment in patients who develop malignancy.
Physicians should consider the delayed onset of pembrolizumab effect before initiating treatment in patients with poorer prognostic features and/or aggressive disease.